Sunlenca Kit
Product Images NDC 61958-3002

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sunlenca (NDC 61958-3002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gilead Sciences, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Sunlenca 01)

Sunlenca 300 mg kit includes two vials, two vial access devices, two syringes, and two injection needles. The kit components are illustrated and labeled separately, showing the contents provided for the injectable dosage form. Labeler is Gilead Sciences, Inc.*

FDA Label Image

Figure 2 (Sunlenca 02)

Instructional diagram illustrating the preparation and administration steps for Sunlenca (LENACAPAVIR SODIUM) 300 mg/1 kit. Steps include preparing the vial and syringe with yellow solution, preparing the vial access device, attaching and filling the syringe, preparing an injection site on the patient's abdomen, attaching the injection needle and expelling air bubbles, injecting 1.5 mL subcutaneously, and administering the second injection at a new site.*

FDA Label Image

Chemical Structure (Sunlenca 03)

Chemical structure of lenacapavir sodium depicted as a molecular diagram showing its atomic connectivity and functional groups.*

FDA Label Image

Principal Display Panel (300 mg Tablet Blister Pack Pouch Carton)

Sunlenca (lenacapavir) tablets 300 mg per tablet, in a pouch containing 4 tablets. The label includes storage instructions (20-25 °C), caution to keep out of reach of children, and manufacturing information by Gilead Sciences, Inc. The label design features red and blue circular graphics.*

FDA Label Image

Principal Display Panel (5 Tablet Blister Pack Pouch Carton)

Sunlenca (lenacapavir) tablets 300 mg per tablet packaging label showing that one pouch contains 5 tablets. The label includes storage instructions, a warning to keep out of reach of children, and manufacturer information for Gilead Sciences, Inc., made in Canada.*

FDA Label Image

Principal Display Panel (Kit Carton)

Sunlenca (lenacapavir) injection kit label showing strength as 463.5 mg/1.5 mL (309 mg/mL) for subcutaneous injection. The kit contents include two 1.5 mL single-dose vials of lenacapavir, vial access devices, syringes, injection needles (22 gauge, 1/2 inch), prescribing information, instructions, and patient information. Labeler is Gilead Sciences, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.